ID | 63708 |
フルテキストURL | |
著者 |
Makimoto, Go
Department of Allergy and Respiratory Medicine, Okayama University Hospita
Misawa, Mahito
Department of Hematology, Ako Central Hospital
Maeda, Yoshinobu
Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Kaken ID
researchmap
Kiura, Katsuyuki
Department of Allergy and Respiratory Medicine, Okayama University Hospita
ORCID
Kaken ID
publons
researchmap
|
抄録 | Dasatinib, an effective second-generation tyrosine kinase inhibitor, is used to treat breakpoint cluster region-Ableson-positive chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphocytic leukemia. One common adverse event associated with dasatinib use is fluid retention, including pleural effusion. Chylothorax, however, is a rare adverse event. Although the precise mechanism of dasatinib-induced chylothorax is unclear, almost all cases involve right or bilateral chylothorax, and mostly occur within 5 years of dasatinib initiation. Here, we report a rare case of a patient with dasatinib-induced massive left chylothorax 10 years after dasatinib initiation, which improved after dasatinib termination and a switch to bosutinib.
|
キーワード | Chronic myeloid leukemia
Chylothorax
Dasatinib
|
発行日 | 2022
|
出版物タイトル |
Respiratory Medicine Case Reports
|
巻 | 37巻
|
出版者 | Elsevier
|
開始ページ | 101662
|
ISSN | 2213-0071
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
OAI-PMH Set |
岡山大学
|
著作権者 | © 2022 The Authors.
|
論文のバージョン | publisher
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
関連URL | isVersionOf https://doi.org/10.1016/j.rmcr.2022.101662
|
ライセンス | http://creativecommons.org/licenses/by-nc-nd/4.0/
|